Analyst Price Target is $64.50
▲ +52.16% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Vaxcyte in the last 3 months. The average price target is $64.50, with a high forecast of $70.00 and a low forecast of $52.00. The average price target represents a 52.16% upside from the last price of $42.39.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in Vaxcyte.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.